Literature DB >> 30181171

Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade.

Deepak Mittal1, Dipti Vijayan1, Mark J Smyth2.   

Abstract

Overexpression of CD38 after PD-1/PD-L1 blockade increases extracellular adenosine levels and may contribute to acquired resistance to anti-PD-1/PD-L1 therapy. Cancer Discov; 8(9); 1066-8. ©2018 AACRSee related article by Chen et al., p. 1156. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30181171     DOI： 10.1158/2159-8290.CD-18-0798

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  14 in total

Review 1.  The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.

Authors:  Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-09       Impact factor: 4.249

Review 2.  Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

Review 3.  Targeting natural killer cells in solid tumors.

Authors:  Guillaume Habif; Adeline Crinier; Pascale André; Eric Vivier; Emilie Narni-Mancinelli
Journal:  Cell Mol Immunol       Date:  2019-03-25       Impact factor: 11.530

4.  Cell type-specific transcriptomics of esophageal adenocarcinoma as a scalable alternative for single cell transcriptomics.

Authors:  Max Krämer; Patrick S Plum; Oscar Velazquez Camacho; Kat Folz-Donahue; Martin Thelen; Isabel Garcia-Marquez; Christina Wölwer; Sören Büsker; Jana Wittig; Marek Franitza; Janine Altmüller; Heike Löser; Hans Schlößer; Reinhard Büttner; Wolfgang Schröder; Christiane J Bruns; Hakan Alakus; Alexander Quaas; Seung-Hun Chon; Axel M Hillmer
Journal:  Mol Oncol       Date:  2020-04-21       Impact factor: 6.603

5.  Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway.

Authors:  Dongwei Dou; Xiaoyang Ren; Mingli Han; Xiaodong Xu; Xin Ge; Yuanting Gu; Xinxing Wang
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

Review 6.  The Role of Natural Killer Cells in Autoimmune Diseases.

Authors:  Umut Can Kucuksezer; Esin Aktas Cetin; Fehim Esen; Ilhan Tahrali; Nilgun Akdeniz; Metin Yusuf Gelmez; Gunnur Deniz
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 7.  Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.

Authors:  Yu Yuan; Abdalla Adam; Chen Zhao; Honglei Chen
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

8.  Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections.

Authors:  Min Ye; Dan Huang; Qiongyan Zhang; Weiwei Weng; Cong Tan; Guangqi Qin; Wenhua Jiang; Weiqi Sheng; Lei Wang
Journal:  Cancer Cell Int       Date:  2020-05-24       Impact factor: 5.722

9.  Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.

Authors:  Kyriakos P Papadopoulos; Nehal Lakhani; Gerald S Falchook; Gosia Riley; Johan Baeck; Karen S Brown; Gilad Gordon; Lidya Le; Judy S Wang
Journal:  Cancer Immunol Immunother       Date:  2020-09-28       Impact factor: 6.968

Review 10.  Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.

Authors:  Anna Passarelli; Michele Aieta; Alessandro Sgambato; Cesare Gridelli
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.